Top > Search of International Patents > CANCER VACCINE

CANCER VACCINE

Foreign code F120006485
File No. S2010-0447-C0
Posted date May 7, 2012
Country WIPO
International application number 2011JP057777
International publication number WO 2011122611
Date of international filing Mar 29, 2011
Date of international publication Oct 6, 2011
Priority data
  • P2010-078625 (Mar 30, 2010) JP
Title CANCER VACCINE
Abstract A cancer vaccine which can be used for the prevention and treatment of cancer. Disclosed are: a peptide which can efficiently induce an immune response to cancer and which comprises SEQ ID No. 1 (KMHIRSHTL) or SEQ ID No. 2 (RTFSRMSLL); an antigen presenting cell which displays the peptide on the cell surface thereof; a T cell which is induced by the antigen presenting cell; a cancer vaccine which contains the peptide, an expression vector which expresses said peptide, and an antigen presenting cell which displays the peptide or a T cell which is induced by the antigen presenting cell. Further disclosed is a cancer treatment and prevention method using the cancer vaccine.
Outline of related art and contending technology BACKGROUND ART
In recent years, in cancer immunology, cancer antigens recognized by immune cells has been elucidated that the mechanism is significant. According to this method, first, an antigen presenting cell is dendritic cells (dendritic cells or DC), within the cell, the protein expressed by a cancer is generated when decomposing the antigenic peptide 8-10 amino acids, or major histocompatibility antigen complex (major histocompatibility complex MHC; in humans, human leukocyte antigen or HLA) to and presented on the cell surface. Cytotoxic T cells (cytotoxic T lymphocyte or CTL) is, a dendritic cell surface of class I HLA and an antigen conjugated to the peptides can be recognized, activation, growth, and invade into the tumor, cancer cells with the protein derived from the antigenic peptides the cells against injury (for example, 126 Arch.Surg. (1990): 200-205 reference).
Using this mechanism, a method for treating cancer have been developed as a cancer vaccine. For example, an antigenic peptide derived from a cancer - specific protein presented on the cell surface of dendritic cells produced in vitro, grown, or administered to cancer patients, that was trained by the dendritic cells to administer cytotoxic T cells by, cancer in the patient's body to induce cancer immunity. Or, a cancer - specific protein administered to a cancer patient, the patient's body, throughout the course of the cancer to induce immune mechanisms in (for example, Science (1991) 254:1643-1647, J.Exp.Med. (1996) 183:1185-1192, J. Immunol. (1999) 163:4994-5004, Proc.Natl.Acad.Sci.USA (1995) 92: 432-436, Science (1995) 269:1281-1284, 186 J.Exp.Med. (1997): 785-793 reference).
Scope of claims (In Japanese)請求の範囲 [請求項1]
 配列番号1(KMHIRSHTL)または配列番号2(RTFSRMSLL)の配列からなるペプチド。

[請求項2]
 配列番号1または2の配列からなるペプチドを細胞表面に提示した抗原提示細胞。

[請求項3]
 請求項2に記載の抗原提示細胞によって誘導され、snail抗原を発現しているがん細胞を認識するT細胞。

[請求項4]
 細胞傷害性T細胞であることを特徴とする請求項3に記載のT細胞。

[請求項5]
 前記がん細胞が、膵臓癌細胞、メラノーマ細胞、白血病細胞、あるいは大腸癌細胞であることを特徴とする、請求項3または4に記載のT細胞。

[請求項6]
 配列番号1、2から選択される一つ以上のペプチド、前記ペプチドを発現する発現ベクター、請求項2に記載の抗原提示細胞、または、請求項3~5のいずれかに記載のT細胞を含有するがんワクチン。

[請求項7]
 Snailタンパク質を発現するがん細胞に対するがんワクチンであることを特徴とする請求項6に記載のがんワクチン。

[請求項8]
 前記がんが、膵臓癌、メラノーマ、白血病、または大腸癌であることを特徴とする、請求項6または7に記載のがんワクチン。

[請求項9]
 ヒト以外の脊椎動物に対する、請求項8に記載のがんワクチンを用いたがんの治療・予防方法。

  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • KEIO UNIVERSITY
  • Inventor
  • KUDO, Chie
  • KAWAKAMI, Yutaka
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IS KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PE PG PH PL PT RO RS RU SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ MD RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
Please contact us by E-mail or facsimile if you have any interests on this patent.

PAGE TOP

close
close
close
close
close
close